

Att. Dkt. No. 034536-0726

1652
Box 8eq

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregory D. PLOWMAN et al.
Title: NOVEL PROTEIN PHOSPHATASES AND DIAGNOSIS AND TREATMENT
OF PHOSPHATASE-RELATED DISORDERS
Appl. No. 10/049,515
Filing Date: 06/14/2002
Examiner: Rebecca E. Prouty
Art Unit: 1652

RESPONSE TO NOTICE TO COMPLY

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Notice to Comply mailed on July 28, 2004, in the above-identified application, the Applicants submit the following:

- Return Copy of Notice to Comply (1 page)
- Amendment (3 pages)
- Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821-1.825 (1 page)
- Paper Copy of Sequence Listing (34 pages)
- 1 Diskette containing Computer Readable Format of sequence listing.


Applicants believe there is no fee due, however, the Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount,

unsigned, post-dated, otherwise improper or informal or even entirely missing, the
Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 11 August 2004

By



FOLEY & LARDNER LLP

Customer Number: 22428


Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Beth A. Burrous

Attorney for Applicant

Registration No. 35,087



Notice to Comply

Application No.

10049515

Examiner

Rebecca E.. Prouty

Applicant(s)

PLOWMAN ET AL.

Art Unit

1652

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-308-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY